Illumina Showcases Innovative Genomic Solutions at CIIE to Advance Human Health

● The latest desktop sequencer, the MiSeq™ i100 series, made its global premiere and Asian debut at the 7th China International Import Expo (CIIE), securing on-site signings with its first batch of customers;

● Three Latest Products, Four Major Themes: Showcasing Cutting-Edge Technologies and Solutions in Genomics and Artificial Intelligence;

● Ramping up local investment, announcing the establishment of a new customer experience center in Beijing, and planning to localize production of its latest products;

● Illumina Becomes One of the First Exhibitors to Sign Up for the 8th China International Import Expo, Demonstrating Long-Term Confidence in the Chinese Market and a Firm Commitment to Advancing International Cooperation;

● To empower cutting-edge scientific research and innovative clinical studies in China, facilitate the global expansion of Chinese biotechnology enterprises, and jointly promote biotechnological innovation in the Guangdong-Hong Kong-Macao Greater Bay Area, Illumina will sign more than ten major collaborative agreements with leading Chinese scientific research and clinical institutions and industry partners, including Peking Union Medical College Hospital, Shanghai Innovation Center for Infectious Diseases and Immunology, Westlake University, Changping Institute for Translational Medicine of Biological Samples, and the Chinese Alliance for Rare Diseases.

● Strategically position in the pharmaceutical market, promote innovation in China’s pharmaceutical industry, and establish a new strategic partnership with the China Association for Pharmaceutical Innovation;

● Upholding the concept of sustainability, over 60% of construction materials are recyclable, and more than 90% of display items are reusable;

Shanghai, China, November 5, 2024 – Today, Illumina, the global leader in gene sequencing and array technology, made its debut at the 7th China International Import Expo (CIIE) under the theme “Seeing the Unknown, Charting a New Course Together.” Showcasing innovative technologies, products, and solutions tailored for the future and diverse application scenarios, Illumina joined hands with partners across industry, academia, research, and healthcare to jointly chart a new course for human health.

Illumina Booth

At this year’s China International Import Expo (CIIE), Illumina structured its presence around four thematic pillars—“Science,” “Technology,” “Human Health,” and “Mission”—showcasing a comprehensive lineup of low-, mid-, and high-throughput sequencing “flagship” platforms, including the newly launched MiSeq™ i100 series. The company also highlighted its cutting-edge research achievements and genomics artificial intelligence product, PrimateAI-3D.

Furthermore, during the exhibition, Illumina will host a series of themed days centered on “Technological Innovation, Cutting-Edge Science, Healthcare, and Environmental Sustainability,” while showcasing end-to-end solutions across numerous fields, including oncology, large-scale population cohort studies, genetics and reproduction, microbiology, and agriculture. From basic research to clinical diagnostics, and from small-scale laboratories to large-scale sequencing centers, Illumina’s one-stop offerings meet diverse market needs, empowering researchers and healthcare professionals with greater precision and efficiency.

During the current exhibition, Illumina signed an agreement with the Bureau of the China International Import Expo (CIIE), becoming one of the first exhibitors to sign up for the 8th CIIE. Wu Zhengping, Deputy Director of the CIIE Bureau, attended the unveiling ceremony for Illumina’s new products making their global debut and delivered remarks stating: “As a significant measure for China to open its market to the world, the CIIE has become an important platform for sharing opportunities in the Chinese market globally and driving economic growth. We are pleased to see Illumina, a global leader in gene sequencing and chip technology, presenting new products that are making their global and Asian debuts here. We also look forward to Illumina leveraging the CIIE’s open and inclusive platform for innovative cooperation to foster a virtuous cycle of ‘promoting innovation through cooperation and strengthening cooperation through innovation’ within the research, clinical, and industrial ecosystems.”

Wu Zhengping, Deputy Director of the China International Import Expo Bureau, and Zheng Lei, Global Senior Vice President and General Manager of Greater China at Illumina, signed an agreement to participate in the 8th CIIE.

At this year’s China International Import Expo (CIIE), Illumina made the global premiere and Asian debut of its MiSeq i100 series desktop sequencers—the most user-friendly and fastest instruments in its product portfolio to date. This innovative product features breakthrough 4-hour sequencing turnaround, streamlined and intuitive operation, and reliable, high-quality data output. By fully leveraging the innovative advantages of room-temperature storage and transportation of reagents, it will help bring next-generation sequencing to a broader range of laboratories.

Global Debut and Asian Premiere of the MiSeq i100 Series Desktop Sequencer Unveiling Ceremony

MiSeq i100 Series Desktop SequencerThe MiSeq i100 series desktop sequencer features a completely new design, integrating XLEAP-SBS chemistry and on-instrument DRAGEN analysis software. It offers a one-touch sequencing workflow for applications in microbiology, infectious diseases, oncology, and other fields, delivering a plug-and-play flexible experience with high-efficiency operation that yields results on the same day. Whether it is securing the golden window for critical care, rapidly containing viral spread, or performing sequencing under stringent environmental conditions, the MiSeq i100 series will reshape the possibilities for scientific and clinical research.

On the opening day of the China International Import Expo (CIIE), Illumina signed on-site agreements with its first batch of local customers, including Westlake University, and announced plans to accelerate the localized manufacturing of the MiSeq i100 series, thereby expanding its application prospects in China. Meanwhile, Illumina announced the establishment of a new China Customer Experience Center in Beijing, aimed at strengthening local collaboration on innovative solutions, comprehensively enhancing customer experience, and promoting local innovation as well as international exchange. The center is scheduled to be completed and open in 2025.

 Illumina Holds Roundtable Discussion with Experts from the Guangdong Provincial Institute of Public Health

Since entering the Chinese market in 2005, Illumina has continuously empowered local innovation and technology translation, providing professional support for the synergistic advancement of the “triple-chain integration” of the innovation chain, industrial chain, and value chain. During this China International Import Expo (CIIE), Illumina will join hands with leading Chinese research, clinical institutions, and industry partners to sign more than ten major cooperation agreements. These collaborations will focus on cutting-edge technologies in genomics, continuously introducing the latest global technologies and expertise to the Chinese market, and promoting the global implementation of “Chinese solutions” in life sciences and precision medicine.

● withPeking Union Medical College Hospital and the Chinese Alliance for Rare DiseasesEstablish a tripartite collaboration to jointly advance scientific research, talent training, international exchanges, and the widespread adoption of standardized clinical applications in the field of complex and rare diseases in China;

● withShanghai Center for Innovation in Infectious Diseases and ImmunologySigned a strategic cooperation agreement to advance clinical cohort studies in the elderly population and exploratory research on drug mechanisms;

● withBeijing Changping District Life Valley Institute for Biospecimen TranslationAchieve cooperation, promote international exchanges and collaboration on large-scale cohort projects, accelerate the localized application of innovative technological products, and strengthen the training and development of professional talent;

● withChina Pharmaceutical Innovation Promotion AssociationForging a New Strategic Partnership to Build China’s Pharmaceutical Innovation Ecosystem, Fostering Local Innovation and Synergistic Industrial Development.

● andNovogeneEstablish collaboration, deepen global strategic partnerships, and accelerate the globalization of Chinese biotechnology enterprises;

● withHong Kong, China Partner: Xiangda BiotechnologyJointly promote the accelerated implementation of innovative technological solutions in the Guangdong-Hong Kong-Macao Greater Bay Area.

Zheng Lei, Global Senior Vice President and General Manager of Greater China at Illumina, stated: “With its openness, inclusiveness, and emphasis on innovative collaboration, the China International Import Expo (CIIE) has created an unparalleled platform for exchange and cooperation. Through these strategic partnerships, Illumina will not only promote synergistic industrial development but also actively explore and expand ‘China-specific solutions’ tailored to local needs, fully empowering the future development of China’s precision medicine and genetic testing industries, and leading a new chapter in life sciences.”

As a model green enterprise in the global biotechnology industry, Illumina put its sustainability philosophy into practice at this CIIE, adhering to the principle of hosting an eco-friendly exhibition. The booth employed a modular construction strategy, with 60% of the building materials being recyclable, reusable, and renewable; over 90% of the main display items are designed for circular use. Meanwhile, the themed exhibition area featured intangible cultural heritage “origami art” and exclusively used recycled paper materials.

Illumina is dedicated to advancing and inspiring the development of genomics to continuously improve human health. Our focus on innovation has established us as a global leader in gene sequencing and array technologies, enabling us to provide professional services to customers in research, clinical, and applied markets worldwide. Our products are widely used in life sciences, oncology, reproductive health, agriculture, and other emerging fields.